Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Array BioPharma Gains on Colorectal Cancer Study Success

Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.

Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

Pfizer's Eczema Candidate Meets All Goals in Phase III Study

Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS

Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

Mark Vickery headshot

Top Research Reports for Alphabet, Eli Lilly & CVS Health

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Eli Lilly (LLY) and CVS Health (CVS).

Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues

Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.

Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down

Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure

Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...

Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.

Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice

Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales

AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.

Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales

Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.